Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

Bruton’s tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma

Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. So, overcoming resistance of EGFR TKIs has...

Full description

Bibliographic Details
Main Authors: Chi-Tai Yeh, Tzu-Tao Chen, Pamungkas Bagus Satriyo, Chun-Hua Wang, Alexander T. H. Wu, Tsu-Yi Chao, Kang-Yun Lee, Michael Hsiao, Liang-Shun Wang, Kuang-Tai Kuo
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Oncogenesis
Online Access:https://doi.org/10.1038/s41389-021-00345-8

Internet

https://doi.org/10.1038/s41389-021-00345-8

Similar Items